

CollPlant Holdings Ltd.**("The Company")**

June 14, 2015.

To:

The Tel Aviv Stock Exchange Ltd. Israel Securities Authority

www.tase.co.ilwww.isa.gov.il

Dear Sir/Madam,

RE: Approval of Chief Scientist for 2015

The Company is pleased to announce that it has obtained approval from the Chief Scientist of the Ministry of Economy for the research & development plan of CollPlant Ltd., a fully-owned subsidiary of The Company (CollPlant), for the year 2015. Approval of the Chief Scientist refers to plans for the production of collagen from transgenic plants and its use for the development of regenerative medicine products developed by CollPlant, including a product for the treatment of tendinopathy, a product for treatment of acute and chronic wounds, and other products. This approval is in conformity with the Encouragement of Industrial Research and Development Law and subject to a number of obligations, limitations, and suspending conditions as is customary in letters of approval of this type, including the dispensing of royalties to the state from all CollPlant revenues.

The extent of approved research & development expenses for CollPlant totals approximately NIS 9.34 million. The approved grant rates are 50% and the approved grant of the Chief Scientist for the year 2015 totals approximately NIS 4.7 million as compared with NIS 4.4 million which was approved in the previous year.

About CollPlant

CollPlant is a clinical-stage regenerative medicine company leveraging its proprietary, plant-based rhCollagen technology for the development and commercialization of tissue repair products, initially for the orthobiologics and advanced wound care markets. The Company's cutting-edge technology is designed to generate and process proprietary recombinant human collagen (rhCollagen), among other patent-protected recombinant proteins. Given that CollPlant's rhCollagen is identical to the type I collagen produced by the human body, it offers significant

advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company's broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: VergenixTMSTR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; VergenixTMFG (Flowable Gel) wound filler, for treatment of acute and chronic wounds, and; VergenixTMBVF (Bone Void Filler), for use in spinal fusion procedures and trauma. CollPlant's business strategy includes proprietary development and manufacturing of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacturing and marketing of additional products.

For more information about CollPlant, visit <http://www.collplant.com>